Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – March 30, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]
Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable to Confo on net sales Confo to have a co-investment option Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery […]
Ghent, Belgium – October 28, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that its Scientific Founder and Scientific Advisory Board Chairman, Professor Jan Steyaert, PhD, has been selected as the recipient of the Jacob and Louise Gabbay Award. Each year the award, administered by […]
Ghent, Belgium – September 15, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it will present highlights from the preclinical profiling of CFTX-1554, Confo’s lead clinical candidate in neuropathic pain, during the International Association for the Study of Pain (IASP) 2022 World Congress on […]
Ghent, Belgium – June 28, 2022 – Confo Therapeutics announced today that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The award further validates and supports Confo’s leadership in the discovery of novel GPCR (G protein-coupled receptor) drug candidates using its proprietary universal ConfoBody® technology, specifically for the […]
Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. The newly added patents (US-11,162,953, US-11,162,954, EP 3557254 and EP […]
— Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery — Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® […]
Confo Therapeutics Establishes Medical Advisory Board Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. The international […]
Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development […]
Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development Ghent, Belgium – October 15, 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, fragment-based […]
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.